Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
961-980 of 2,251 trials

Atrial Fibrillation: New Drug Treatment After Stent Surgery

We are studying whether a simpler medication regimen can safely prevent blood clots and serious heart issues in patients with irregular heartbeat after coronary stent implantation. This trial compares it to the current standard treatment involving multiple medications.

Acute Coronary SyndromeAtrial FibrillationAtrial Flutter>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Constipation Prevention in Critically Ill Children: PEG3350+E Treatment

We are studying whether a special solution can help prevent constipation in critically ill children. The trial also looks at the safety of this treatment and compares stool consistency in different patient groups.

Constipation≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyPediatrics

CART Cell Therapy for Acute Lymphoblastic Leukemia in Young Patients

We are studying the safety and feasibility of new CART cell therapies for children and young adults with relapsed or refractory acute lymphoblastic leukemia. This trial aims to find better treatment options for those who have not responded to current therapies.

Acute Lymphoblastic Leukemia (ALL)>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Burning Mouth Syndrome: Clonazepam Treatment Study

We are exploring how a topical treatment with clonazepam affects pain and other symptoms in people with burning mouth syndrome. The study will also look at patient preferences and experiences with the treatment over time.

Burning Mouth Syndrome6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyPsychiatry

Pulmonary Aspergillosis: MIRAGE Imaging Study

We are testing a new imaging method using a radioactive substance to see if it helps visualize lung infections caused by Aspergillus. This study aims to improve diagnosis and understanding of this condition.

Pulmonary AspergillosisEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Nephrotic Syndrome: Rituximab Treatment Comparison

We are comparing two Rituximab treatment plans for adults with relapsing nephrotic syndrome. The goal is to find out which regimen better prevents relapses and improves quality of life.

Nephrotic Syndrome1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyNephrology

Metastatic Colorectal Cancer: Regorafenib with Chemotherapy

We are studying whether combining Regorafenib with metronomic chemotherapy and low-dose aspirin helps patients with chemo-resistant metastatic colorectal cancer live longer without disease progression. We will also look at quality of life and treatment side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Severe von Willebrand Disease: New Treatment Study

We are testing a new treatment for children with severe von Willebrand Disease to see if it helps control bleeding episodes and is safe during surgeries. The study will compare this treatment with and without an existing medication.

Von Willebrand's Factor Deficiency>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Metastatic Colorectal Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with metastatic colorectal cancer who have not responded to standard care. The study aims to see if this new drug can improve survival and response rates compared to existing treatments.

Metastatic Colorectal CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

COVID-19 Treatment: Nirmatrelvir/Ritonavir for Children

We are studying a new oral medication for children with COVID-19 who are at risk of severe illness. The trial will evaluate its safety, how well it works, and how it is tolerated in young patients.

COVID-19Efficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Ulcerative Colitis in Kids: Vedolizumab vs. Infliximab

We are comparing the safety and effectiveness of a new treatment, vedolizumab, with the standard treatment, infliximab, for children aged 6-17 with ulcerative colitis. This study aims to find out which treatment works better for young patients.

Ulcerative Colitis3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Oxygen Levels at Birth: The HiLo-Trial

We are studying whether giving very low birthweight infants 60% oxygen instead of 30% at birth can improve their development by 18-24 months. This research aims to find the best approach for resuscitating preterm infants.

PrematurityConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Localized Prostate Cancer: Darolutamide and Radiation Therapy

We are studying the effects of darolutamide with or without radiation therapy in patients with localized prostate cancer at high risk of relapse. The goal is to see if this combination improves survival and quality of life.

Localized Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: JAK Inhibitor Dose Tapering Study

We are exploring whether reducing the dose of JAK inhibitors helps maintain low disease activity in rheumatoid arthritis patients. This study will also look at the impact on pain, function, and overall quality of life.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesRheumatology

Ibrutinib for Autoimmune Hemolytic Anemia in CLL Patients

We are studying whether ibrutinib can effectively treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia or similar conditions. The trial will also look at the safety and quality of life during treatment.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Non-Small Cell Lung Cancer: Cemiplimab with Chemotherapy

We are studying whether adding new cancer treatments to cemiplimab and chemotherapy helps patients with operable non-small cell lung cancer. This trial aims to evaluate the effectiveness and safety of these combined treatments.

Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Childhood Leukemia: Inotuzumab Ozogamicin vs. ALLR3

We are studying whether Inotuzumab Ozogamicin works better than standard treatment for children with high-risk first relapse B-cell leukemia. The trial focuses on safety and long-term effectiveness in young patients.

Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

De-escalating Treatment for HER2-Positive Metastatic Breast Cancer

We are studying whether reducing treatment is safe for patients with undetectable cancer levels after long-term therapy. This trial aims to assess the impact on survival and quality of life.

HER2-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Oligometastatic Colorectal Cancer: OPTIMISE Study

We are exploring whether a blood test can help decide the best treatment for patients with oligometastatic colorectal cancer. The study also looks at how this approach affects quality of life and treatment costs.

Colorectal Cancer with MetastasisEfficacy phase (II)No PlaceboStandard MedicinesOncology

Chronic Rhinosinusitis with Nasal Polyps: Dupilumab Study

We are exploring how Dupilumab may improve nasal barrier function in patients with Chronic Rhinosinusitis with nasal polyps. This study compares the effects of treatment on nasal cells from patients and healthy controls.

Chronic Rhinosinusitis with Nasal PolypsChronic Rhinosinusitis without Nasal Polyps>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology